Allergan, Pfizer call off proposed $160B merger
[...] the two drugmakers will focus on other strategies to boost profits and sales quickly, with Pfizer saying it will decide by year's end whether to separate its global established products business, which sells older, mostly off-patent drugs. The companies' decision could deter other tax inversions in the works — exactly the impact the Obama administration is seeking by having Treasury issue 300-plus pages of new regulations that remove or reduce key financial benefits of a tax inversion. With... Читать дальше...